Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the dose of LY573636-sodium (hereafter referred to as
LY573636) that can be administered safely in combination with liposomal doxorubicin in
patients with advanced cancer who have failed a prior treatment.
The study consists of a dose escalation phase to the maximum tolerated dose (MTD) and a dose
confirmation phase in patients with platinum resistant epithelial ovarian, fallopian tube or
primary peritoneal cancer who have never been treated with doxorubicin.